CY1106198T1 - Γονιδιακη θepαπεια που διαμεσολαβειται απο αδενοϊο - Google Patents

Γονιδιακη θepαπεια που διαμεσολαβειται απο αδενοϊο

Info

Publication number
CY1106198T1
CY1106198T1 CY20061101473T CY061101473T CY1106198T1 CY 1106198 T1 CY1106198 T1 CY 1106198T1 CY 20061101473 T CY20061101473 T CY 20061101473T CY 061101473 T CY061101473 T CY 061101473T CY 1106198 T1 CY1106198 T1 CY 1106198T1
Authority
CY
Cyprus
Prior art keywords
adenoe
gene therapy
mediated gene
adenovirus
useful
Prior art date
Application number
CY20061101473T
Other languages
Greek (el)
English (en)
Inventor
Seppo Yla-Herttuala
Anu-Maaria Sandmair
Sami Loimas
Matti Vapalahti
Original Assignee
Ark Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106198(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Limited filed Critical Ark Therapeutics Limited
Publication of CY1106198T1 publication Critical patent/CY1106198T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20061101473T 1998-11-06 2006-10-13 Γονιδιακη θepαπεια που διαμεσολαβειται απο αδενοϊο CY1106198T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (1)

Publication Number Publication Date
CY1106198T1 true CY1106198T1 (el) 2011-06-08

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101473T CY1106198T1 (el) 1998-11-06 2006-10-13 Γονιδιακη θepαπεια που διαμεσολαβειται απο αδενοϊο

Country Status (18)

Country Link
US (1) US6579855B1 (cg-RX-API-DMAC7.html)
EP (1) EP1135513B2 (cg-RX-API-DMAC7.html)
JP (1) JP4733833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020013473A (cg-RX-API-DMAC7.html)
CN (1) CN1184321C (cg-RX-API-DMAC7.html)
AT (1) ATE341639T1 (cg-RX-API-DMAC7.html)
AU (1) AU749451B2 (cg-RX-API-DMAC7.html)
CA (1) CA2348624C (cg-RX-API-DMAC7.html)
CY (1) CY1106198T1 (cg-RX-API-DMAC7.html)
DE (1) DE69933468T3 (cg-RX-API-DMAC7.html)
DK (1) DK1135513T4 (cg-RX-API-DMAC7.html)
ES (1) ES2273521T5 (cg-RX-API-DMAC7.html)
GB (1) GB9824437D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0104046A3 (cg-RX-API-DMAC7.html)
NO (1) NO330776B1 (cg-RX-API-DMAC7.html)
PL (1) PL193076B1 (cg-RX-API-DMAC7.html)
PT (1) PT1135513E (cg-RX-API-DMAC7.html)
WO (1) WO2000028059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) * 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
AU2024207005A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
KR20260113057A (ko) 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
US6579855B1 (en) 2003-06-17
AU749451B2 (en) 2002-06-27
PT1135513E (pt) 2006-12-29
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
ES2273521T5 (es) 2011-12-28
CN1325450A (zh) 2001-12-05
DE69933468T2 (de) 2007-01-11
CA2348624A1 (en) 2000-05-18
NO20012220L (no) 2001-05-04
NO20012220D0 (no) 2001-05-04
AU1385100A (en) 2000-05-29
EP1135513B1 (en) 2006-10-04
ATE341639T1 (de) 2006-10-15
JP4733833B2 (ja) 2011-07-27
PL349489A1 (en) 2002-07-29
PL193076B1 (pl) 2007-01-31
NO330776B1 (no) 2011-07-11
HUP0104046A2 (hu) 2002-01-28
EP1135513B2 (en) 2011-08-10
DE69933468T3 (de) 2012-01-19
KR20020013473A (ko) 2002-02-20
CN1184321C (zh) 2005-01-12
DK1135513T4 (da) 2011-11-21
DK1135513T3 (da) 2006-11-27
WO2000028059A1 (en) 2000-05-18
GB9824437D0 (en) 1999-01-06
ES2273521T3 (es) 2007-05-01
CA2348624C (en) 2012-07-31
JP2002529097A (ja) 2002-09-10
EP1135513A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
DK1135513T4 (da) Adenovirus-medieret genterapi
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
ITMI991608A0 (it) Sonda elettrochirurgica per il trattamento di tumori mediante radiofre quenza
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
BR9608651A (pt) Método para o tratamento de hiperplasia prostática benigna com terapia térmica
FI971568A0 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
PT1075315E (pt) Iluminador para terapia fotodinamica
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
ITMI962745A0 (it) Sonda-catetere per il trattamento di tumori di organi parenchimatosi con ipertermia interstiziale indotta da radiofrequenza
NO972228D0 (no) Nytt tumorsuppresor-gen, HIC-1
PT752870E (pt) Utilizacao de mycobacterium para o tratamento de tumores
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20006047D0 (no) Fremgangsmåte for genterapi
EP0896055A4 (en) APOPTOSIS INDUCING PROTEIN AND THIS CODING GENE
MXPA01012040A (es) Uso terapeutico de la melatonina.
HUP0101947A3 (en) Combination for the treatment of tumors
CY1106194T1 (el) Θepαπευτικη αγωγη της δυσκινησιας
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
AU5778399A (en) Gene therapy for treatment of cancer